NYSE · DNA

Ginkgo Bioworks Holdings, Inc.

Healthcare · Biotechnology

$6.78▼ 0.15% ($0.01)at close

After hours$6.80▲ 0.29%7:40 PM ET

52-week

$5.37$17.58

What the market price implies · Reverse DCF

Historical revenue grew by -14.19%/yr over the past 4 years.

Selected forecast · Base scenario

0.8%/yr · actual 10-year annualized revenue growth

Year 1 growth: 0%

Market-implied · Base operating assumptions + edited margins

Unavailable · flat 10-year annualized revenue growth

Reverse DCF solves revenue growth itself using Base operating assumptions and your edited margins. Changing forecast growth alone does not change the implied rate. This is a model-implied requirement, not an analyst forecast.

No supported revenue growth rate matches this price with these operating assumptions.

Valuation

Recommended · Revenue & margin DCF

Price used

$6.78

Estimated value / share

Unavailable

Base scenario

USD · TTM ending 2026-06-30

Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.

Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.

Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.

Year 1 growth 0% · Ending margin 0% · Discount rate 14.67%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future revenue, operating margins, and the investment needed to support them.

Price timestamp: Sep 10, 2026, 8:00 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 11, 2026, 1:08 AM UTC · provider

Why this method?

There is not a stable run of positive FCFF to anchor a direct cash-flow CAGR, so the model should start from revenue and margin assumptions instead.

Is FCFF positive and has it been for 3+ consecutive years? Latest FCFF is not positive.

Price vs Fundamentals

Why The Stock Is Moving

Likely fundamental deteriorationModerate confidence

1Y Price: -34.11%Revenue (TTM): -51.54%FCF (TTM): 30.66%P/S: 33rd pct

What changed

The stock fell 34.11% over the last year. Revenue declined 51.54% over the trailing twelve months. Operating margin moved from -135.74% to -259.86%. Free cash flow grew 30.66% over the trailing twelve months.

What the market seems to be pricing

The market is reacting to weaker business momentum more than just compressing the valuation multiple. Even if the shares already screen cheap on P/S, investors are still discounting lower future earnings power.

What would invalidate this read

Operating margin stands at -259.86%. Revenue declined 51.54% — this read reverses if that trend stabilizes. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.

Performance

Return analysis

Company profile

Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States.

CEOJason Kelly

SectorHealthcare

IndustryBiotechnology

Employees485

IPO dateApr 19, 2021

https://www.ginkgo.bio

Market multiples

Forward P/E—

EV/EBITDA-2.88

Enterprise value$733.54M

Stock splits

Aug 20, 2024↓ Reverse

Every 40 shares became 1

-97%

Profitability & growth

Revenue growth-59.37%

Gross margin80.09%▼1.5ppvs FY2024

Operating margin-259.86%▲61.3ppvs FY2024

ROE-56.29%▼5.2ppvs FY2025

Analyst consensus

RatingBuy

Target price$5.00▼26.25%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 5, 2026

Q4 FY26 · EPS est -$0.58 · Revenue est $21.57M

View